Immunogenic composition for paratuberculosis
AssigneeHAV Vaccines Limited
InventorJohn HERMON-TAYLOR
Life of this patent
Estimating the term…
Abstract
A vaccine comprising a polypeptide comprising an amino acid sequence of at least 9 contiguous amino acids from the N-terminal region of MAP P900, or a polynucleotide encoding said polypeptide, for use in a method of treating or preventing MAP infection or a condition or symptom associated with MAP infection in a subject.
Claims28
A Mycobacterium avium subspecies paratuberculosis (MAP) vaccine comprising a polynucleotide encoding a polypeptide which comprises a fragment of MAP P900, wherein the fragment of MAP P900 has a length of up to 150 amino acids and comprises an amino acid sequence of at least 9 contiguous amino acids from the region of MAP P900 shown in SEQ ID NO:
- 2.
(canceled)
(canceled)
(canceled)
17-18. (canceled)
The MAP vaccine of claim 17, wherein the additional MAP polypeptide is at least one of the following:
- a ahpC polypeptide, a gsd polypeptide, a p12 polypeptide and a mpa polypeptide, wherein:
- (a) said ahpC polypeptide has the amino acid sequence given in SEQ ID NO:
- 32;
- and/or
- (b) said gsd polypeptide has the amino acid sequence given in SEQ ID NO:
- 34;
- and/or
- (c) said pl2 polypeptide has the amino acid sequence given in SEQ ID NO:
- 36 or SEQ ID NO:
- 38;
- and/or
- (d) said mpa polypeptide bas the amino acid sequence given in SEQ ID NO:
- 40.
22-36. (canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.